TrianglePUBLICATIONS · 38382001
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2024 Jun 10
- First author
- Janjigian YY
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Janjigian YY
- type
- Author
- name
- Ajani JA
- type
- Author
- name
- Moehler M
- type
- Author
- name
- Shen L
- type
- Author
- name
- Garrido M
- type
- Author
- name
- Gallardo C
- type
- Author
- name
- Wyrwicz L
- type
- Author
- name
- Yamaguchi K
- type
- Author
- name
- Cleary JM
- type
- Author
- name
- Elimova E
- type
- Author
- name
- Karamouzis M
- type
- Author
- name
- Bruges R
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Janjigian YY
- type
- Author
- name
- Ajani JA
- type
- Author
- name
- Moehler M
- type
- Author
- name
- Shen L
- type
- Author
- name
- Garrido M
- type
- Author
- name
- Gallardo C
- type
- Author
- name
- Wyrwicz L
- type
- Author
- name
- Yamaguchi K
- type
- Author
- name
- Cleary JM
- type
- Author
- name
- Elimova E
- type
- Author
- name
- Karamouzis M
- type
- Author
- name
- Bruges R
- type
- Author
- bibliography ids
- nci-bib-68316b837efeaddf0a226732
- book metadata
- content sha256
- fba10827e852c44395cde65790a20f548cd6fe191e0cc3ef8fce40ab23d50796
- document type
- citation
- dois
- 10.1200/JCO.23.01601
- electronic publication date
- display
- 2024 Feb 21
- precision
- day
- year
- 2024
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:38382001
- immutable id
- pubmed:38382001@fba10827e852c44395cde65790a20f548cd6fe191e0cc3ef8fce40ab23d50796
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- 1527-7755
- issn print
- 0732-183X
- issue
- 17
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 2012-2020
- volume
- 42
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 38382001
- provenance
- batch id
- 6d213eecf21b6b7867cb
- provider
- NCBI PubMed ESummary
- record sha256
- abe0961900e174b96ecd98f72559534b19da7f24d2f14ee2f9d3e7215f41f3af
- response sha256
- 684f894a21d8f5f78a3bd0acd8ee4215ff94144487c53dab1056650ee8d6751d
- retrieved at
- 2026-09-09T23:48:19.049083+00:00
- publication date
- display
- 2024 Jun 10
- precision
- day
- year
- 2024
- publication types
- Journal Article
- Clinical Trial, Phase III
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.
Preserved source evidence · Not medical advice